Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. Calcitonin gene-related peptide - beyond migraine prophylaxis

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Ageing as a risk factor for neurodegenerative disease

    Publikation: Bidrag til tidsskriftReviewpeer review

  3. Post-traumatic headache: epidemiology and pathophysiological insights

    Publikation: Bidrag til tidsskriftReviewpeer review

  4. Does inflammation have a role in migraine?

    Publikation: Bidrag til tidsskriftReviewpeer review

  5. CGRP as the target of new migraine therapies - successful translation from bench to clinic

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. Neurovascular contact plays no role in trigeminal neuralgia secondary to multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Fibrinogen: A potential biomarker for predicting disease severity in multiple sclerosis

    Publikation: Bidrag til tidsskriftReviewpeer review

  3. Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • MAGNIMS Study Group
Vis graf over relationer

Early evaluation of treatment response and prediction of disease evolution are key issues in the management of people with multiple sclerosis (MS). In the past 20 years, MRI has become the most useful paraclinical tool in both situations and is used clinically to assess the inflammatory component of the disease, particularly the presence and evolution of focal lesions - the pathological hallmark of MS. However, diffuse neurodegenerative processes that are at least partly independent of inflammatory mechanisms can develop early in people with MS and are closely related to disability. The effects of these neurodegenerative processes at a macroscopic level can be quantified by estimation of brain and spinal cord atrophy with MRI. MRI measurements of atrophy in MS have also been proposed as a complementary approach to lesion assessment to facilitate the prediction of clinical outcomes and to assess treatment responses. In this Consensus statement, the Magnetic Resonance Imaging in MS (MAGNIMS) study group critically review the application of brain and spinal cord atrophy in clinical practice in the management of MS, considering the role of atrophy measures in prognosis and treatment monitoring and the barriers to clinical use of these measures. On the basis of this review, the group makes consensus statements and recommendations for future research.

OriginalsprogEngelsk
TidsskriftNature reviews. Neurology
Vol/bind16
Udgave nummer3
Sider (fra-til)171-182
Antal sider12
ISSN1759-4758
DOI
StatusUdgivet - mar. 2020

ID: 61519561